Seroatlas · Human Serome Atlas

NPR2

Atrial natriuretic peptide receptor 2

Also known as: AMDM, ANPb, ANPRB, ANPRB_HUMAN, GC-B, GUCY2B, NPRB

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P20594
Gene: NPR2
Ensembl: ENSG00000159899
Chromosome: 9
Canonical length: 1047 aa
Protein class: Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene encodes natriuretic peptide receptor B, one of two integral membrane receptors for natriuretic peptides. Both NPR1 and NPR2 contain five functional domains: an extracellular ligand-binding domain, a single membrane-spanning region, and intracellularly a protein kinase homology domain, a helical hinge region involved in oligomerization, and a carboxyl-terminal guanylyl cyclase catalytic domain. The protein is the primary receptor for C-type natriuretic peptide (CNP), which upon ligand binding exhibits greatly increased guanylyl cyclase activity. Mutations in this gene are the cause of acromesomelic dysplasia Maroteaux type. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

1047 residues, UniProt reviewed canonical sequence.

>P20594|NPR2
     1  MALPSLLLLV AALAGGVRPP GARNLTLAVV LPEHNLSYAW AWPRVGPAVA LAVEALGRAL
    61  PVDLRFVSSE LEGACSEYLA PLSAVDLKLY HDPDLLLGPG CVYPAASVAR FASHWRLPLL
   121  TAGAVASGFS AKNDHYRTLV RTGPSAPKLG EFVVTLHGHF NWTARAALLY LDARTDDRPH
   181  YFTIEGVFEA LQGSNLSVQH QVYAREPGGP EQATHFIRAN GRIVYICGPL EMLHEILLQA
   241  QRENLTNGDY VFFYLDVFGE SLRAGPTRAT GRPWQDNRTR EQAQALREAF QTVLVITYRE
   301  PPNPEYQEFQ NRLLIRARED FGVELGPSLM NLIAGCFYDG ILLYAEVLNE TIQEGGTRED
   361  GLRIVEKMQG RRYHGVTGLV VMDKNNDRET DFVLWAMGDL DSGDFQPAAH YSGAEKQIWW
   421  TGRPIPWVKG APPSDNPPCA FDLDDPSCDK TPLSTLAIVA LGTGITFIMF GVSSFLIFRK
   481  LMLEKELASM LWRIRWEELQ FGNSERYHKG AGSRLTLSLR GSSYGSLMTA HGKYQIFANT
   541  GHFKGNVVAI KHVNKKRIEL TRQVLFELKH MRDVQFNHLT RFIGACIDPP NICIVTEYCP
   601  RGSLQDILEN DSINLDWMFR YSLINDLVKG MAFLHNSIIS SHGSLKSSNC VVDSRFVLKI
   661  TDYGLASFRS TAEPDDSHAL YAKKLWTAPE LLSGNPLPTT GMQKADVYSF GIILQEIALR
   721  SGPFYLEGLD LSPKEIVQKV RNGQRPYFRP SIDRTQLNEE LVLLMERCWA QDPAERPDFG
   781  QIKGFIRRFN KEGGTSILDN LLLRMEQYAN NLEKLVEERT QAYLEEKRKA EALLYQILPH
   841  SVAEQLKRGE TVQAEAFDSV TIYFSDIVGF TALSAESTPM QVVTLLNDLY TCFDAIIDNF
   901  DVYKVETIGD AYMVVSGLPG RNGQRHAPEI ARMALALLDA VSSFRIRHRP HDQLRLRIGV
   961  HTGPVCAGVV GLKMPRYCLF GDTVNTASRM ESNGQALKIH VSSTTKDALD ELGCFQLELR
  1021  GDVEMKGKGK MRTYWLLGER KGPPGLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NPR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 11 nTPM

Expression across tissuesHPA

Tissue

blood vessel: 11 nTPM
endometrium: 8.7 nTPM
cervix: 8.2 nTPM
adipose tissue: 6.6 nTPM
cerebellum: 6 nTPM
fallopian tube: 5.7 nTPM

Single-cell type

adrenal medulla cells: 21 nCPM
leydig cells: 13 nCPM
fibro-adipogenic progenitors: 13 nCPM
gonadotrophs: 12 nCPM
müller glia: 12 nCPM
peritubular myoid cells: 12 nCPM

Immune cell

plasmacytoid DC: 0.5 nTPM
memory CD8 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

pons: 14 nTPM
cerebellum: 14 nTPM
hypothalamus: 14 nTPM
medulla oblongata: 12 nTPM
thalamus: 11 nTPM
midbrain: 11 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NPR2.

Disease | AllUniProt

Conditions NPR2 is implicated in, by any mechanism.

Acromesomelic dysplasia 1 (AMD1) MIM:602875
Epiphyseal chondrodysplasia, Miura type (ECDM) MIM:615923
Short stature with non-specific skeletal abnormalities 1 (SNSK1) MIM:616255

Disease | GeneticClinVar

100 pathogenic / likely-pathogenic of 743 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Acromesomelic dysplasia 1, Maroteaux type
Tall stature-scoliosis-macrodactyly of the great toes syndrome
Short stature with nonspecific skeletal abnormalities
NPR2-related disorder
Short stature with nonspecific skeletal abnormalities 1

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.5
gnomAD pLI: 0
gnomAD missense Z: 2.96
DepMap mean gene effect: -0.14
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NPR2 as an antibody target. Whether an autoantibody or antibody against NPR2 could matter depends on whether native NPR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NPR2 is annotated at the cell surface, where native NPR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NPR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...